Xaliptine 5 mg/ml Concentrate for solution for infusion 10ml Vial

Product Details

Xaliptine 5 mg/ml Concentrate for Solution for Infusion is a specialized medication designed for the treatment of certain types of cancer. This product contains Pemetrexed, an antineoplastic agent that works by targeting specific metabolic pathways essential for cancer cell growth and division. It is typically administered in a clinical setting by healthcare professionals.

Benefits of Use

• Xaliptine (Pemetrexed) is indicated for the treatment of malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer (NSCLC).
• It acts as a multi-targeted antifolate, disrupting the synthesis of DNA and RNA, thereby inhibiting cancer cell proliferation.
• Can be used as a monotherapy or in combination with other chemotherapeutic agents, depending on the specific cancer type and treatment regimen.

How to Use

1. Xaliptine 5 mg/ml Concentrate is for intravenous infusion only and must be administered under the supervision of a qualified physician experienced in the use of antineoplastic agents.
2. The concentrate must be diluted prior to use with appropriate sterile diluents (e.g., 0.9% sodium chloride injection) to achieve the required infusion concentration.
3. The exact dose and duration of treatment will be determined by the treating physician, based on the patient's condition, body surface area, and renal function.
4. Ensure adequate hydration and appropriate premedication, including folic acid and vitamin B12 supplementation, as advised by the healthcare provider to minimize toxicity.
5. The infusion should be administered slowly over a specified period, typically 10 minutes.

Caution & Warnings

• Xaliptine should only be administered by healthcare professionals in a facility equipped to manage cytotoxic chemotherapy.
• Patients must be pre-medicated with corticosteroids, folic acid, and vitamin B12 to reduce the incidence and severity of drug-related toxicity.
• Regular monitoring of blood counts (including complete blood count with differential), renal function, and liver function is crucial during treatment.
• May cause severe myelosuppression, which can lead to life-threatening infections and bleeding.
• Not recommended for use in pregnant or breastfeeding women due to potential harm to the fetus or infant.
• Use with caution in patients with renal impairment, and dosage adjustments may be necessary.
• Avoid concomitant administration with NSAIDs in patients with mild to moderate renal impairment.
• Inform your doctor of all medications and supplements you are currently taking before starting Xaliptine therapy.

Ingredients

Active Ingredient: Pemetrexed (as Pemetrexed disodium heptahydrate)
Concentration: 5 mg/ml
Excipients: Not provided. For a complete list of excipients, please refer to the official package leaflet or consult with a healthcare professional.